Drugs / Glutamine
Glutamine
also known as
L-Glutamine · AES-14 · Dipeptiven · Endari · FEMA NO. 3684 · Glutamin · Glutamina · L-Glutamin \&Chios Mastiha · +4 more
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | NUTRESTORE | — | 2004-06-10 | fda.gov ↗ |
Trials 60 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 16 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT05569993 Comparator | Oct 2022 → Oct 2023 | traumatic brain injury | Assiut University | Unknown | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT05655819 Comparator | Feb 2023 → Dec 2025 | dyspepsia | David J. Cangemi | Completed | No outcome recorded |
| Phase 1/2 | NCT04507945 Background | Oct 2020 → Sep 2021 | bowel dysfunction | Nanjing University School of Medicine | Unknown | No outcome recorded |
| Phase 1/2 | NCT02589145 Background | Jun 2016 → Apr 2019 | lymphoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02701673 Background | Jun 2016 → Jun 2019 | lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT01983969 Background | Nov 2013 → Nov 2017 | cancer of unknown primary site, lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07053761 Comparator | Jun 2025 → Jun 2026 overdue | radiation proctitis | Peking University First Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT02961816 Background | Jun 2017 → Jun 2021 | lymphoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02114502 Background | Sep 2014 → Sep 2018 | plasma cell myeloma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02012608 Comparator | Jun 2014 → Apr 2019 | breast cancer | University of Arkansas | Terminated | No outcome recorded |
| Phase 2 | NCT01414244 Comparator | Nov 2010 → Dec 2015 | irritable bowel syndrome | Tulane University | Completed | No outcome recorded |
| Phase 2 | NCT00255229 Comparator | Dec 2002 → Jan 2010 | colorectal cancer | AHS Cancer Control Alberta | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00318331 Comparator | May 2006 → Sep 2007 | critical illness polyneuropathy, infectious disease with sepsis, respiratory failure | Christiana Care Health Services | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07287592 Comparator | Dec 2025 → Dec 2026 expected | cancer, peripheral neuropathy | Ain Shams University | Not yet recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07442084 Comparator | Mar → Nov 2025 | polyp of large intestine | Xi'an Hospital of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT01704664 Comparator | Mar 2007 → Jul 2021 | gastric cancer | Medical University of Bialystok | Unknown | No outcome recorded |
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 79 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | glutamine | “Oral therapy with pharmaceutical-grade l-glutamine (USAN, glutamine) has been shown to increase the proportion of the reduced form of nicotinamide adenine dinucleotides in...” PMID 30021096 ↗ Jul 201859“The intervention includes a personalised pharmaconutrition formula containing arginine, glutamine, and beta-hydroxy-beta-methylbutyrate (HMB).” NCT07466758 ↗ “the use of growth hormone, glutamine, modified diet and other measures proposed intestinal rehabilitation treatment.” NCT04507945 ↗ “Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.” NCT03113240 ↗ “2 intervention periods: glutamine (0.5 g/kg/d) and placebo, 4 months each” PMID 19421321 ↗ May 2009 “Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day” NCT04693936 ↗ “Drug: Glutamine” NCT01263041 ↗ |
| Known as | AES-14 | “Compare the efficacy of a new preparation of glutamine (AES-14) vs placebo in reducing the incidence of grade 3 or 4 chemotherapy-induced oral mucositis during the first course...” NCT00334984 ↗ |
| Known as | Dipeptiven | “Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag.” NCT01704664 ↗ |
| Known as | Endari | ChEMBL registry synonym — accepted as the source's own label CHEMBL930 ↗ |
| Known as | FEMA NO. 3684 | ChEMBL registry synonym — accepted as the source's own label CHEMBL930 ↗ |
| Known as | Glutamin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02998931 ↗ |
| Known as | Glutamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL930 ↗ |
| Known as | L-Glutamin \&Chios Mastiha | “Glutamine (L-Glutamin \&Chios Mastiha) 1 tablet per day” NCT04693936 ↗ |
| Known as | L-Glutamine | “This daily intervention over 3 months combines 4 g L-serine, 14 g L-glutamine, 3 g L-arginine, 2.5 g N-acetylcysteine, 5.75 g L-citrulline, 1 g vitamin C, and 5 g creatine to...” NCT06967428 ↗16“The aim of this study is to investigate the effect of parenteral L-Glutamine supplementation added to enteral nutrition on short-term ICU mortality (7 days) in Covid-19...” NCT04909905 ↗ “L-glutamine, L-arginine and calcium beta-hydroxy-beta-methylbutyrate” NCT04701463 ↗ |
| Known as | Levoglutamide | ChEMBL registry synonym — accepted as the source's own label CHEMBL930 ↗ |
| Known as | NSC-27421 | ChEMBL registry synonym — accepted as the source's own label CHEMBL930 ↗ |
| Known as | Nutrestore | ChEMBL registry synonym — accepted as the source's own label CHEMBL930 ↗ |
| Known as | Nutritional Supplement | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00013923 ↗ |
| Action | Restore | “Glutamine supplementation can normalize this defect in mTORC1.” NCT04019769 ↗ |
| Modality | Other / unclassified | “Glutamine is considered a conditionally essential amino acid during critical illness.” NCT00178581 ↗ |
| Route | Intravenous | “glutamine or alanine IV over the last 5 hours” NCT00005889 ↗ |